Vaccines

6 June 2017

NIH and Themis Bioscience announce the initiation of a clinical trial of a Chikungunya vaccine

6 June 2017

ImmunoCellular Therapeutics Announces Data from ICT-121 Phase 1 Trial in Recurrent Glioblastoma at ASCO 2017

5 June 2017

Heat Biologics Presents Poster on its Phase 2 Trial Evaluating HS-410 at ASCO Annual Meeting

5 June 2017

Immune Design Updates Positive Data from Lead Cancer Immunotherapy Programs at ASCO Annual Meeting

4 June 2017

Dendreon Announces New Findings Demonstrating Durable and Robust Killer T-Cell Response with PROVENGE

4 June 2017

NovaDigm Therapeutics Awarded $6 Million by U.S. Department of Defense to Conduct a Phase 2a Staphylococcus aureus Vaccine Trial

2 June 2017

Inovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 Checkpoint Inhibitor

1 June 2017

Vaxon announces results of its Phase IIb lung cancer trial of Vx-001, a therapeutic vaccine based on optimized cryptic peptides

30 May 2017

European Commission Approves Pfizer’s TRUMENBA® to Help Prevent Meningococcal Group B Disease in Adolescents and Adults

30 May 2017

Imcyse obtains authorization to launch Phase 1b trial in Type 1 diabetes

24 May 2017

Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study

23 May 2017

United Neuroscience Reports Positive Phase 1 Results for Active Vaccine UB-311 in Alzheimer’s Disease

18 May 2017

VAXIMM Announces Data from Phase I Trial in Glioblastoma with Oral T-cell Immunotherapy VXM01 to be Presented at ASCO 2017 Annual Meeting

14 May 2017

Dendreon Announces Results of New PROCEED Registry Analysis Showing Overall Survival Benefit with PROVENGE® in Men with Metastatic Prostate Cancer

11 May 2017

Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy

10 May 2017

Argos Provides Update on its ADAPT Trial Following Meeting with FDA

10 May 2017

EpiThany Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of Avelumab and EP-101 STEMVAC in Breast Cancer

9 May 2017

NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer

9 May 2017

VAXIMM Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of VXM01 with Avelumab in Glioblastoma and Colorectal Cancer in Phase I/II Clinical Studies

8 May 2017

Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy

4 May 2017

Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus

3 May 2017

VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study

3 May 2017

First ever evidence of treatment-induced reduction in HIV reservoirs: ABX464, ABIVAX’ lead drug candidate, impacted HIV blood reservoir in a Phase IIa clinical trial (ABX464-004)

2 May 2017

Yisheng Biopharma Starts Enrollment in Phase 1 Immuno-Oncology Clinical Trial of YS-ON-001 in Patients with Advanced Solid Tumors

24 April 2017

Matinas BioPharma Presents Positive Preclinical Data of Orally Available DNA Vaccines at the 27th Annual European Congress of Clinical Microbiology and Infectious Diseases

24 April 2017

Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers

20 April 2017

Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform

19 April 2017

Bavarian Nordic Announces Initiation of Phase 2 Combination Trial of PROSTVAC, Ipilimumab and Nivolumab in Patients with Localized Prostate Cancer

19 April 2017

Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial

19 April 2017

Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins